Loading clinical trials...
Loading clinical trials...
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
Conditions
Interventions
Mirvetuximab soravtansine plus Bevacizumab
Bevacizumab
Locations
264
United States
Usa Mitchell Cancer Institute /ID# 269661
Mobile, Alabama, United States
Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987
Phoenix, Arizona, United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573
Irvine, California, United States
Moores Cancer Center at UC San Diego /ID# 269564
La Jolla, California, United States
Kaiser Permanente - Los Angeles Medical Center /ID# 269541
Los Angeles, California, United States
University Of California Irvine Medical Center /ID# 269572
Orange, California, United States
Start Date
March 15, 2023
Primary Completion Date
April 1, 2027
Completion Date
May 1, 2032
Last Updated
February 23, 2026
NCT03050268
NCT06257264
NCT06964009
NCT00539162
NCT06710548
NCT05005403
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions